3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
33
Neoplasms
18
Colorectal Neoplasms
3
Skin Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Diseases
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Biliary Tract Neoplasms
1
Advanced BRAF-mutant Cancers
1
Interventions
pembrolizumab
15
Nivolumab
10
Ipilimumab
7
cemiplimab
6
dabrafenib
4
binimetinib
4
Dacarbazine
4
trametinib
3
encorafenib
3
Drug Therapy
3
Allovectin-7
3
zanolimumab
2
talabostat
2
lifileucel
2
aldesleukin
2
Vemurafenib
2
Tablets
2
Semaxinib
2
Intravital Microscopy
2
Interleukin-2
2
Fluorouracil
2
vitespin
1
veliparib
1
varlilumab
1
tozuleristide
1
tin etiopurpurin
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Neoplasms
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA
NCT01683188
2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4
Terminated
53 enrolled